The collaboration targets minimally invasive tools to detect alpha-synuclein and other co-pathologies in Parkinson's disease and Alzheimer's disease, aiming to support earlier diagnosis, clinical trials and precision medicine.
verifying reliability
No specialized terms available for this topic.